There are number of challenges in the development of a HIV vaccine. Dr Zoe Moodie (Fred Hutchinson Cancer Center, Seattle, WA, USA) joins touchINFECTIOUS DISEASES to discuss the challenges and the current status in the development of HIV vaccines.
The presentation entitled ‘Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T cell correlates of HIV-1 acquisition risk’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
- What are the challenges of developing a vaccine against HIV? (00:25)
- What is the current status of HIV vaccine development? (01:08)
Disclosures: Zoe Moodie has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Vaccines
Ruth Link-Gelles, IDWeek 2022: Efficacy of COVID-19 vaccination in paediatric populations
In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States. Interviews available in this series: Real world […]
Ruth Link-Gelles, IDWeek 2022: Real world effectiveness of paediatric COVID-19 vaccination
COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss real-world findings of […]
Michael Ison, IDWeek 2022: Respiratory syncytial virus (RSV) – Health burden and current vaccine candidates
Respiratory syncytial virus (RSV) present a significant disease burden in children and older adults. Currently, there are no approved vaccines against RSV. In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the health burden of RSV infection in older adults, and current […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!